SCHEMBL4293875

SCHEMBL4293875

COc1cc(NC(C)=O)c(I)c(OC)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.51
MAPT P10636 3/20 0.49
ALDH1A1 P00352 3/20 0.49
HTT P42858 3/20 0.49
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
PKM P14618 1/20 0.48
HSD17B1 P14061 1/20 0.48
HSD17B2 P37059 1/20 0.48
CYP1A1 P04798 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP1B1 Q16678 1/20 0.48
GAA P10253 3/20 0.45
TP53 P04637 1/20 0.45
USP2 O75604 1/20 0.44
CYP3A4 P08684 1/20 0.44
MAPK1 P28482 1/20 0.44
LMNA P02545 3/20 0.43
PTK2 Q05397 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27730870 0.87 CYP1A1 (0.48) SMN1; SMN2MAPTALDH1A1HTTMEN1
SCHEMBL20922186 0.81 SMN1; SMN2 (0.49) SMN1; SMN2MAPTALDH1A1HTTKDM4E
SCHEMBL4768748 0.80 CYP1A1 (0.43) SMN1; SMN2MAPTALDH1A1HTTKDM4E
SCHEMBL9837774 0.80 SMN1; SMN2 (0.60) SMN1; SMN2MAPTALDH1A1HTTKDM4E
SCHEMBL374670 0.80 HSD17B1 (0.48) SMN1; SMN2MAPTALDH1A1HTTKDM4E
SCHEMBL16071797 0.80 HSD17B1 (0.48) SMN1; SMN2MAPTALDH1A1HTTKDM4E
SCHEMBL3924189 0.77 SMN1; SMN2 (0.54) SMN1; SMN2MAPTALDH1A1HTTKDM4E
SCHEMBL7959792 0.77 MAPT (0.50) SMN1; SMN2MAPTALDH1A1KDM4EMEN1
SCHEMBL2502603 0.76 MAPT (0.71) SMN1; SMN2MAPTALDH1A1HTTKDM4E
SCHEMBL2191052 0.76 HSD17B1 (0.75) SMN1; SMN2MAPTALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2630129-B1 QUINOXALINE DERIVATES MERCK PATENT GMBH (DE) 2016-10-26 EP disclosed
US-8895559-B2 Quinoxalines derivatives and pharmaceutical compositions and kits MERCK PATENT GMBH (DE) 2014-11-25 US disclosed
US-8895559-B2 Quinoxalines derivatives and pharmaceutical compositions and kits MERCK PATENT GMBH (DE) 2014-11-25 US disclosed
US-20130217670-A1 QUINOXALINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-08-22 US disclosed
US-20130217670-A1 QUINOXALINE DERIVATIVES MERCK PATENT GMBH (DE) 2013-08-22 US disclosed
WO-2012052102-A1 QUINOXALINE DERIVATES MERCK PATENT GMBH (DE) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217670-A1 QUINOXALINE DERIVATIVES PIK3R5, NQO2, PIK3R1 SMN1; SMN2 2735/4885MAPT 4120/4885ALDH1A1 2771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.